IBio Initiates Preclinical Study of Obesity Antibody After 77% Fat Reduction in Mice

GLP-1 receptor agonists, initially developed for type 2 diabetes, have become prominent treatments for obesity and weight loss, demonstrating significant effectiveness in managing metabolic disorders and reducing body fat. iBio has advanced a first-in-class Activin E antibody, IBIO-610, which shows promise in enhancing weight loss and preventing weight regain when combined with GLP-1 therapy, with ongoing studies in non-human primates expected to provide further insights. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued warnings for women using GLP-1 drugs to employ effective contraception due to potential risks during pregnancy, underscoring the importance of medical supervision especially amid unregulated drug access. In the UK, fitness professionals are being trained to provide informed advice on GLP-1 weight loss drugs, addressing widespread misinformation and emphasizing the necessity of lifestyle changes alongside medication to maintain muscle mass and overall health. Dr. David A. Kessler shares a personal account of successful weight loss using GLP-1 drugs, highlighting the role of brain chemistry and the prevalence of ultra-formulated foods in the obesity epidemic. While GLP-1 drugs offer dual benefits for diabetes and obesity, ongoing discussions focus on their long-term safety, accessibility challenges, and broader societal implications.